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Abstract 
Background: Recently a screen from a library of 1.8 million compounds identified in vitro a potent activity of the 
2-aminobenzimidazoles series against Leishmania infantum, the etiological agent responsible by over 20.000 deaths 
each year. Several analogs were synthesized and in vitro tested through an optimization program, leading to a prom-
ising 2-aminobenzimidazoles derived compound (2amnbzl-d) that was progressed to in vivo mice studies. However, 
the not expected toxic effects prevented its progression to more advanced preclinical and clinical phases of drug 
development. Due to limitations of cell models in detecting whole organism complex interactions, 90% of the com-
pounds submitted to pre-clinical tests are reproved. The use of Zebrafish embryo models could improve this rate, sav-
ing mammals, time and costs in the development of new drugs. To test this hypothesis, we compared 2amnbzl-d with 
two compounds with already established safety profile: carbamazepine and benznidazole, using an embryo Zebrafish 
platform based on acute toxicity, hepatotoxicity, neurotoxicity and cardiotoxicity assays (Pltf-AcHpNrCd).
Results: Tests were performed blindly, and the results demonstrated the presence of lethal and teratogenic effects 
(CL50%: 14.8 µM; EC50%: 8.6 µM), hepatotoxic in concentrations above 7.5 µM and neurotoxic in embryos exposed 
to 15 µM of 2amnbzl-d. Nevertheless, benznidazole exposition showed no toxicity and only the 100 µM of carbamaz-
epine induced a bradycardia.
Conclusions: Results using Pltf-AcHpNrCd with zebrafish reproduced that found in the toxicological tests with mam-
mals to a portion of the costs and time of experimentation.
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Background
Currently, the tests used in toxicological screening are 
costly, time-consuming, and not satisfactorily predictive, 
thus toxicity is one of the major attritions causes during 
the drug development process. The placement of a new 
drug on the market takes about 8  years, with a cost of 
approximately US $ 1 billion [1]. Despite this, about 90% 
of the drugs in development fail in the clinical stages and 
are discontinued, leading to the loss of a large volume 
of investment [2]. Considering this problem, there is a 
recurring discussion about improving the risk prediction 
of new compound in the early stages of its development 
to optimize the development of new drugs and the use of 
animals in regulatory trials.
In vitro studies with cell cultures are poor predictors of 
drug absorption, distribution, metabolism and excretion 
(ADME) in whole organism, on the other hand, in  vivo 
studies help to understand the possible toxic proper-
ties of new drugs, but they are time-consuming, expen-
sive and use a limited number of animals. Zebrafish 
embryos and larvae with up to 120  h of life have been 
considered unprecedented toxicological models, which 
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possess fully integrated vertebrate organ systems [3]. 
Thus, zebrafish can bridge the gap between in vitro safety 
assays and mammals’ models in a fast and cost-effective 
manner and would have a key role in accelerating the 
process of new chemicals development, improving pre-
diction, prioritizing safe compounds, and decreasing 
testing time and costs substantially [4–6].
This model has the advantage of having OECD-specific 
guidelines for safety evaluation of chemical compounds 
(acute toxicity), which is performed within 96  h [7]. It’s 
also an excellent model organism to study liver damage 
induced by chemical compounds due to the high degree 
of genetic conservation for enzymes and pathways nec-
essary in drug metabolism, such as ARH receptors, CYP 
enzymes or ADH isoenzymes, present and functional 
since the early stages of development [5, 8]. In the same 
way, cardiovascular physiology is also highly conserved 
between humans and zebrafish at anatomical, cellular, 
and membrane-biology levels, thus many human cardio-
vascular drugs have been shown to have identical effects 
on larvae zebrafish physiology, and numerous human 
cardiovascular disorders have been recapitulated in 
zebrafish genetic model [3, 4]. The neural activity can be 
assessed by embryo neurobehavioral biomarkers, related 
to the neuromuscular function of the central nervous 
system that can indicate possible changes in neural devel-
opment, such as synaptogenesis and glial cell growth 
[9]. Thus, the three main reasons behind the retirement 
of drugs in clinical phases and post market withdrawal 
could possibly have been predicted in embryo and lar-
vae zebrafish trials in the early stages of development and 
saved mammals models (mice, rabbits, dogs, monkeys) 
and billions of dollars invested.
Ferreira et  al. [10] recently published the results of a 
hit-to-lead campaign aiming at the identification of new 
preclinical candidates for the treatment of leishmania-
sis, a potentially fatal neglected disease that affects mil-
lions of people worldwide and whose current treatment 
options are limited either by length of treatment or toxic 
side effects. Starting from a promising 2-aminobendazole 
hit identified via an in vitro phenotypic screen, hundreds 
of analogues were synthetized with the aim of finding a 
molecule capable of killing the parasite and be human 
safe. From these, two promising leads showing a good 
balance of properties were progressed to a 5-day toler-
ability study in healthy mice. The 25 mg/kg/day dose was 
well tolerated, but animals treated with 50 mg/kg/day or 
above showed clinical signs of toxicity. During the fol-
low up study in mice infected with Leishmania, results 
showed lack of efficacy for both compounds and a poor 
safety profile for the 2amnbzl-d lead.
The aim of this study was to evaluate whether the tox-
icity identified during the in vivo studies with the new 
chemical entity 2amnbzl-d published by Ferreira et  al. 
[10] could be predicted by tests using the zebrafish 
model and reduced the time and cost with the tests, 
as well as the use of mammals in research of drug dis-
covery, thus impacting strongly in the 3Rs principles 
(replacement, reduction and refinement).
Results
The acute toxicity of the compounds, performed using 
the OECD guideline 236, demonstrated that embryos 
exposed to 2amnbzl-d in concentrations above 25  µM 
presented lethality significantly different from the 
DMSO control group. The cumulative mortality for 
each concentration can be seen in Fig. 1. The LC50% for 
96 h found was 14.8 µM (Fig. 2). There was no mortal-
ity in the control groups, and there were no incidents 
during the tests that may have influenced the results. 
The tests carried out with exposure of embryos to car-
bamazepine and benznidazole compounds did not pre-
sent acute toxicity in any tested concentration.
Teratogenic effects, represented by curve of malfor-
mations or death, can be seen in Fig. 1. At concentra-
tions of 6.25 and 12.5 µM, the embryos remained alive 
for 96  h of evaluation, but most embryos exposed to 
12.5 µM did not hatch, presented yolk sac hemorrhages 
and bradycardia (Fig. 4), which EC50% 8.57 µM. On the 
other hand, carbamazepine and benznidazole did not 
demonstrate a teratogenic effect on zebrafish embryos 
development at any concentration tested.
To assess cardiotoxicity, hepatotoxicity and neurotox-
icity, the maximum concentration tested of compound 
had as reference the LC50% previously obtained in the 
OECD 236 test. The heart rate data did not show dif-
ferences between the control groups 1% DMSO and 
2amnbzl-d groups or benznidazole groups. Zebrafish 
larvae exposed to 100  µM of carbamazepine showed 
bradycardia (Figs. 3 and 4).
Regarding the hepatotoxic effects, no change in liver 
function was observed in groups of larvae exposed to 
the compound’s carbamazepine and benznidazole at 
all concentrations tested. On the other hand, the pres-
ence of red liver color and the increase in its size and/ 
or retention of the yolk sac, indicative of function liver 
changes, was verified in in larvae groups exposed to 
2amnbzl-d concentrations above 7.5 µM (Figs. 5, 6).
It was observed neurotoxic effects in groups of 
embryos exposed to 15 µM of 2amnbzl-d (Fig. 7). It was 
no differences between spontaneous movements of the 
embryos exposed to carbamazepine and benznidazole 
compared to the 1% DMSO group control, indicating 
the absence of a neurotoxic effect.
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Discussion
Zebrafish embryos develop most of the major organ sys-
tems present in mammals, including the cardiovascular, 
nervous and digestive systems, in in less than a week and 
most of the safety and efficacy assays can be carried out 
with zebrafish embryo and larvae with data generated 
biologically relevant [4]. To endorse the 3Rs principles, 
the tests chosen for the toxicological screening used 
zebrafish embryos and larvae up to 120 hpf, classified as 
in vitro models by international Directives.
2amnbzl-d compound showed important toxicologi-
cal findings in mice and its drug discovery campaign 
was stopped due to toxicity, among other reasons. For 
the purpose of comparing the results obtained with a 
new chemical entity still going through early drug dis-
covery stages, two approved drugs on the World Health 
Organization´s list of essential medicines, benznidazole 
and carbamazepine, were used since their toxicologi-
cal profile is well known. Carbamazepine, a commonly 
prescribed agent for focal epilepsy, neuropathic pain, 
schizophrenia and bipolar disorder [14], common side 
effects include nausea and drowsiness, serious side 
effects may include skin rashes, decreased bone mar-
row function, suicidal thoughts, or confusion. and care 
should be taken in pregnancy in those with either kidney 
or liver problems [15]. Bradycardia has been describ-
ing in patients exposed to high dose of carbamazepine 
[16]. Benznidazole, a drug used for specific treatment of 
Chagas disease [17], common side effects include rash, 
numbness, fever, muscle pain, loss of appetite, and trou-
ble sleeping. It is not recommended during pregnancy or 
in people with severe liver or kidney disease [18].
The zebrafish could be used to accurately predict rela-
tive acute toxicity as rat inhalation, rabbit dermal, and rat 
oral exposures through correlations to 96 hpf zebrafish 
LC50 values [6]. The acute toxicity of compounds was 
performed by OECD Directive 236 and the results dem-
onstrated that 2amnbzl-d was potentially lethal (CL50% 
14.8 µM) and teratogenic (EC50% 8.6 µM) when embryos 
were exposed to concentrations between 6.25 and 
Fig. 1 Survival graph relating the percentage of survival of embryos and health embryos exposed to their respective concentrations of 
carbamazepine (a), benznidazole (b) and 2-aminobenzimidazole-derived (c) by 96 hpf, compared to the DMSO control. To analyze the results, 
Log-rank Statistical Test (Mantel-Cox) was performed to compare all groups with the DMSO control. The p values were corrected by the Bonferroni 
methodology and considered significant for values p < 0.001
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100 µM up to 96 hpf. The embryo developmental malfor-
mations observed, such as the absence of hatching and 
bradycardia, are directly correlated with prenatal loss in 
rabbits [6]. These results corroborate with a recent study 
carried out in rodents for the same compound Ferreira 
et al. [10], the authors observed mortality and distress in 
the mice that were submitted to efficacy tests, finally, the 
development of the compound was discontinued. Thus, 
the use of the zebrafish model could have predicted the 
acute toxicity of the compound within 4 days (96 h), and 
tests on rodents could be avoided. On the other hand, the 
compounds Carbamazepine and Benzimidazole did not 
cause changes in the development of the embryos when 
exposed to concentrations between 6.25 and 100  µM, 
which demonstrates that the OECD 236 test [10] pre-
dicted the safety of these compounds that are currently 
used in the treatment of human diseases and were previ-
ously approved in all preclinical and clinical trials.
An early in vitro safety assessment was conducted in 
which 2amnbzl-d showed low inhibition of the hERG 
channel (IC50 > 30 μM) and the main cytochrome P450 
family enzymes (IC50 > 20  μM), similarly, screening 
against an off-target panel of a panel of 20 marks cover-
ing key human enzymes, kinases and receptors showed 
low interference in the activities (EC50 > 10  µM) as 
Fig. 2 Dose–response curves showing the percentages of death or 
malformation embryos after treatment with each concentration (6.25, 
12.5, 25, 50, 100 µM) of 2-aminobenzimidazole-derived for 96 h. The 
red line represented the fit model calculated by Probit Regression 
 (R2 = 0.865, p < 0.0001) of death embryos and its confidence interval 
of 95% (IC95) (dashed blue line). Horizontal line represented the EC50 
value of 14.8 µM. The green line represented the fit model calculated 
by Probit Regression  (R2 = 0.855, p < 0.0001) of death or malformation 
embryos and its IC95 (dashed blue line) calculated by Medcalc 
Software. Horizontal line represented the EC50 value of 8.6 µM
Fig. 3 Example of cardiographs, representing the time series of patterns of intensity (green channel from RGB) of the horizontal and vertical 
lines (1000 digitized frames), positioned on center of the heart´s larvae. Based on the image pattern formed, the rate and the rhythm of the 
heartbeat were calculated. In image (A), the constant rhythm of the heartbeat of a larva exposed to 12.5 µM of 2-aminobenzimidazole-derived 
can be observed, and in image (B) an altered rhythm of the positive control heartbeat of an exposed larva at 10.0 µM haloperidol (beat heating 
rate = 150 bpm, sample entropy = 1.05 and Poincaré: S = 3267) is showed. In this case, it is possible to observe variable time intervals of cardiac 
contractions (beat heating rate = 186 bpm, sample entropy = 0.11 and Poincaré: S = 8.28)
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well [10]. On the other hand, 2amnbzl-d compound 
showed significant hepatotoxic effects at concentra-
tions above 7.5 µM, as well as neurotoxic effect at con-
centration 15 µM in zebrafish. Zebrafish are vertebrates 
and therefore share a high degree of sequence and 
functional homology with mammals (more than 70%), 
including humans. Discordances between in  vitro/in 
vivo assays are abundant. For example, in experiments 
using immortalized human liver epithelial (THLE) cells 
transfected with plasmid vectors that encoded human 
cytochrome P450s 1A2, 2C9, 2C19, 2D6, or 3A4a, for 
studied the behavior of 103 drugs, the authors found 
that the EC50 are far higher than the estimated  Cmax,u 
concentrations of the majority of the drugs in human 
peripheral blood. The authors justify the results, infer-
ring possible suppression of P450 enzyme activity by 
DMSO, by difference in the accumulation of metabo-
lites within hepatocytes in  vivo at concentrations that 
are much higher than those in peripheral blood due to 
transport across or due to first pass metabolism [19]. 
Often, experiments of cytotoxicity are carried out using 
the MTT as indicator of cellular viability. In a study was 
showed that diverse compound such as drugs, nano-
particles and polypeptides interfere with MTT reduc-
tion rate under/overestimating of the cell viability [20]. 
Off-target activities of drug candidates observed dur-
ing in vitro pharmacological profiling frequently do not 
translate to adverse events in human. Consequences 
of an off-target activity observed during profiling of a 
drug (AMG 337) being evaluated for treatment of solid 
tumors is reported. Screen of 151 potential off-targets, 
did not guarantee that during the clinical trials, head-
ache cause by cerebral vasorelaxation emerged as the 
dose-limiting adverse events in the first-in-human 
trial [21]. In a review about translatability of preclini-
cal science to human applications, authors point out 
that part of problem is associated with low prediction 
of cultured cells or the potential drugs did not have 
Fig. 4 Scatter-plot showing the mean and distribution of the relative alteration of heart rate, and Tukey´s whiskers-plots showing the distribution 
of the sample entropy and Poincaré area values of Danio rerio larvae (96 hpf ) exposed to different concentrations of the molecule carbamazepine 
(a), benznidazole (b) and from 2-aminobenzimidazole-derived (c). The data were analyzed using ANOVA statistical tests and Dunnett’s Multiple 
Comparison Test. (***) p < 0.0001
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good safety feature in animals for unknown reason. 
The authors suggest that a strategy to improve transla-
tional research would be the identification of candidate 
drugs by screening the compound libraries using three 
dimensional (3D) organoids for rapid drug screening 
and model organisms such as Caenorhabditis elegans 
and zebrafish in high-throughput assays [22].
Due to the conservation of cell biological, developmen-
tal and metabolic processes across all vertebrates, studies 
in fish can give great insight into human disease pro-
cesses, to date all proteins studied have a similar function 
in fish and mammals [23]. Thus, the 2amnbzl-d toxico-
logical effects demonstrated in zebrafish and in rodents 
show that the initial in vitro assays were not very predic-
tive of the toxicity of the compound.
In study of Ferreira et al. [10], based on several in vitro 
studies and in vivo pharmacokinetic profiling, 2amnbzl-d 
progressed to a 5-day tolerability study in healthy mice. 
Oral doses of 25, 50 and 100 mg/kg/day were evaluated to 
identify dosing regimens for the follow-up in vivo proof-
of-concept study. In this study, the group tested with 
25 mg/kg/day of 2-aminobenzimidazole derived was well 
tolerated, however, in the group of 50  mg/kg/day, from 
the 3rd day of treatment the animals showed some clini-
cal signs such as piloerection, change in behavior and 
visible irritability. No changes were observed in internal 
organs after euthanasia in day 6. Regarding the maximum 
dose, due to the reduction in body weight and serious 
toxic signs, including mortality, studies were terminated 
on day 3 or 4 of treatment. These studies in rodents could 
be refined and/or avoided, if the results obtained in the 
zebrafish model had been considered before their realiza-
tion. Certain zebrafish endpoints showed correlations to 
rodent and rabbit toxicity (LC50%), such as spontaneous 
Fig. 5 Danio rerio larvae 120 hpf stained with Oil Red O. Larvae exposed to the molecule carbamazepine (a), benznidazole (b) and 
2-aminobenzimidazole derived (c) (72–120 hpf ) (A) Negative control Medium ABNT [11]; (B) DMSO Control 1%, (C) Positive Control Ethanol 2% (D) 
Lower concentration; (E) Intermediate concentration; (F) Higher concentration. Blue arrows indicate the location of the unstained liver. Red arrows 
indicate the stained liver, with indication of hepatic alterations compatibles with steatosis
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movement (neurotoxicity), could be assessed even earlier 
at 24 hpf. Thus, using zebrafish as a model for toxicity 
testing would decrease testing times and costs substan-
tially, in comparison to rodent and rabbit testing with the 
requirement of testing at age 8–12 weeks (rats) or at least 
12 weeks (rabbits) and then observing the animals for a 
minimum of 14 days [6].
Finally, as for the cardiotoxic effects, 2amnbzl-d did not 
show effects in 96 hpf larvae heartbeat, but carbamaze-
pine induced bradycardia at a concentration of 100 µM. 
Despite being a drug approved by regulatory agencies, 
carbamazepine is contraindicated in patients with heart 
problems and may cause some adverse cardiac effects, 
such as heart condition disorder, arrhythmia, atrioven-
tricular block with syncope, bradycardia, congestive 
heart failure, worsening of coronary disease [24]. Heart 
abnormalities were also recorded in rat embryos when 
exposed to carbamazepine above 211.6  µM [25] and 
overdose were seem with dosages higher than 169.28 µM 
(usual therapeutic levels are 16.9  µM to 50.7  µM) [26–
29]. On the other hand, there was no cardiotoxic effect of 
benznidazole in zebrafish larvae, just as there is no men-
tion of heart problems caused by this medication in the 
package insert and in the scientific literature.
Due to their importance in the treatment of dis-
eases, carbamazepine and benznidazole are on the 
World Health Organization´s list of essential medi-
cines, but side effects are fairly common, which were 
also not detected in the Pltf-AcHpNrCd. Other stud-
ies in zebrafish evaluated exposure time or concentra-
tions higher than those used in the present study and 
observed chronic effects in zebrafish early life stage 
test at 105 µM carbamazepine treated for 10 days [30] 
and found carbamazepine growth retardation above 
129.5 µM and EC50% 366.05 µM [31]. Similarly to our 
study, Buchanan-Kilbey et  al. [32], show that both in 
the control group and in those treated with benznida-
zole at concentrations of 3.7–300 µM, there was no sig-
nificant phenotypic change in the embryos, such as (i) 
cardiovascular malformations, including any pericar-
dial edema, changes in heart beat and in blood circula-
tion, (ii) swimming behavior, as assessed by observing 
spontaneous events and responses evoked by a light 
touch on the embryo’s head and finally (iii) embryonic 
death. Thus, the proposed platform was sensible to per-
form an effective screening for approval of new com-
pounds, however, it did not predict the side effects of 
the drugs. New trials must be carried out to try to pre-
dict these side effects.
In the pharmaceutical industry, the majority of com-
pounds subjected to pre-clinical tests fail, and this results 
in a loss of $ 294 million per drug, being that the cardiac, 
hepatic and neurological toxicities the most impact-
ful [33]. According to international ethical regulations, 
zebrafish larvae up to 5  days post fertilization (dpf) are 
considered in vitro models and are accepted as an alter-
native to animal testing [5]. In view of the urgent demand 
for new drugs and the potential that zebrafish must accel-
erate this process by prioritizing safe compounds, as well 
as the need for higher ethical standards of toxicological 
Fig. 6 Percentage of Danio rerio Larvae 120 hpf (n = 25) exposed 
to carbamazepine (a), benznidazole (b) and 2-aminobenzimidazole 
derived (c) positive for hepatotoxicity (Statistical Proportion Test 
"exact" Clopper-Pearson confidence interval for the observed 
proportion Clopper & Pearson [12]; Fleis et al. [13] (***) p < 0.001 in 
comparison with DMSO (1%)
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screenings, the zebrafish model must be included in tests 
before study in mammals to attempt the 3Rs principle.
Conclusions
As significant changes were found in the toxicity tests, 
the 2amnbzl-d is likely to cause acute toxic effects related 
to death or malformations, hepatotoxic and neurotoxic 
effects in concentrations above 4 µM. The present study 
demonstrated that the toxicity of 2amnbzl-d compound 
could have been predicted by the zebrafish model in just 
5 days of evaluation and refined the use of mammals in 
subsequent tests.
Methods
The project was approved by animal ethics commit-
tee from the Federal University of São Carlos (Num-
ber: 5085180319). Test compound 2-aminobendazole 
(purity > 95%), compound 29 [10] and the reference 
standards of two comparator drugs (benznidazole and 
carbamazepine) (purity > 99%) were kindly provided by 
the non-profit R&D organization Drugs for Neglected 
Diseases initiative (DNDi) Latin America.
Toxicological profile of 2-aminobendazole were evalu-
ated according to major endpoints requirement of the 
Food and Drug Administration (FDA), such as acute tox-
icity, cardiotoxicity, neurotoxicity and hepatotoxicity. As 
control, two FDA-approved compounds were screened 
for the same endpoints, Carbamazepine and Benznida-
zole. All tests were carried out blindly.
Zebrafish embryos and larvae used in the test were sup-
plied by the Central Vivarium of the Federal University of 
São Carlos, SP, Brazil, whose matrices are kept in auto-
mated rack at 28° C, pH 7.0, in a photoperiod 14 h light: 
10 h dark and are fed by the feed Gemma®, twice a day. 
To obtain the embryos, breeders were kept in the same 
aquarium overnight in the ratio of 2 males to 1 female 
and the embryos collected in the morning, 10 min after 
fertilization (mpf). Before testing, fertilized embryos 
Fig. 7 Plot showing the means values ± IC95 of the number of spontaneous movements per minute of Danio rerio embryos 24 hpf exposed to 
different concentration of carbamazepine, benznidazole and 2-aminobenzimidazole derived. Images of well showing the results of spontaneous 
movement analysis performed on embryos with 24 hpf, submitted to DMSO (A) or treated with the compounds benznidazole 100 µM (B), 
carbamazepine 100 µM (C), and 2amnbzl-d 15 µM (D). The colored dots represent the movements performed by each embryo. These results 
were generated by the SOFTWARE ESPMOV Count v1.0 that analyzes the number of spontaneous movements from each embryo. The data were 
analyzed using ANOVA statistical tests and Dunnett’s Multiple Comparison Test. (**) p < 0.001
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were selected by observing cell divisions under a micro-
scope (60mpf). The tests were conducted only when the 
fertilization rate was above 90%.
(a) Embryotoxicity: To assess acute toxicity, OECD 
guideline 236 was adopted, in which 200 individuals were 
screened for each compound. Embryos with 1.5  h post 
fertilization (hpf) were exposed to five logarithmic con-
centrations of compound for 96  h (n = 25) in individu-
alized 96-well plates. The viability of the embryos was 
assessed daily according to the observation of endpoints 
lethality indicators such as: embryo coagulation, absence 
of detachment of the yolk sac tail, changes in the forma-
tion of somites and absence of heartbeat [7]. Changes in 
the development of the embryos were recorded daily for 
evaluation of teratogeny. All tests were performed with 
negative control group (E3, n = 25); plate control (E3, 
n = 4), positive control group (3.4 dichloroaniline—4 mg 
 L−1, n = 25) and solvent control group (1% DMSO, 
n = 25).
(b) Cardiotoxicity: To evaluate the effect of the com-
pounds on the heart physiology, the heart rate normal-
ized, and non-linear variability parameters such as area 
of the of the Poincaré Plot and sample entropy were 
analyzed in 50 individuals that were screened for each 
compound following Cornet et  al. [5]. The analyzed 
parameters were chosen based on its capacity in to evalu-
ate the velocity and the rhythm of the cardiac contrac-
tion, often altered in case of cardiotoxicity effects [34].
After 4  h of drug incubation (96–100 hpf), zebrafish 
larvae were anesthetized by immersion in 0.7  mM tric-
aine methanesulfonate (A4050, Sigma-Aldrich, Saint 
Louis, MO, USA) diluted in E3 solution. Embryos treated 
with 10 µM of haloperidol were used as positive cardio-
toxic control. The 1% DMSO treated embryos were used 
as negative cardiotoxic control. Individual hearts were 
recorded during 120 s each (Fig. 3). Videos were acquired 
with a high-speed recording camera (Hamamatsu 
C11440 ORCA-flash 2.8) at 50 fps and analyzed with the 
CardioCount 2 software (Lab. of Applied Immunology—
UFSCAR, São Carlos, Brazil) to assess cardiac parame-
ters. Three base 2 logarithmic dilution of each compound 
and control groups (n = 10) were performed.
(c) Hepatotoxicity: To determine the hepatotoxic effect, 
the liver staining methodology of Zebrafish larvae with 
Oil Red O [8] was used to screened 150 individuals. Oil 
Red O is a lysochrome dye used for staining triglycerides 
and neutral lipids. Two phenotypic outcomes related to 
abnormal liver function were analyzed to assess hepato-
toxicity: hepatic steatosis and lipid retention in the yolk 
sac. After 72 hpf zebrafish larvae were exposed to each 
compound for 48  h and later stained to assess possible 
changes in liver metabolism. Three base 2 logarithmic 
dilutions of each compound and control groups (n = 25) 
were performed. Ethanol 2% was used as positive group 
control. The 1% DMSO was the negative group control. 
Subsequently, the larvae were fixed in 4% paraformal-
dehyde, washed in PBS and subjected to a discoloration 
process, with a solution of  H2O2 (3%) and KOH (0.5%). 
After discoloration, the larvae were washed and evalu-
ated under an optical microscope (Fig. 5).
(d) Neurotoxicity: To evaluate the neurotoxic effect 
of the spontaneous movement at 24 hpf was evaluated 
according to Menelaou et  al. [35] to screened 150 indi-
viduals. 10mpf embryos were exposed for 24  h to three 
base 2 logarithmic dilutions of each compound (n = 30) 
and negative group control (DMSO 1%). The footage of 
embryo spontaneous movement was captured for 6 min, 
with a digital camera attached to an optical microscope. 
The counting of the movements of each embryo was per-
formed using the EspMovCont software (Lab. of Applied 
Immunology—UFSCAR, São Carlos, Brazil), from the 
second minute of filming, totaling 5  min of counting 
(Fig. 7).
(e) Compounds and concentrations: The test concentra-
tions were based on the maximum dilution of the com-
pounds in E3 medium. Maximum concentrations that 
did not observe precipitation after 24 h were selected.
1. Carbamazepine: Molecular weight: 236.3; Solubil-
ity: 100  µM in DMSO (1%) in embryonic medium; 
Embryotoxicity: 6.25  µM, 12.5  µM, 25  µM, 50  µM, 
100 µM; Cardiotoxicity, hepatotoxicity and neurotox-
icity: 25 µM, 50 µM, 100 µM. Total number of indi-
viduals screened: 550.
2. Benznidazole: Molecular weight: 260.2; Solubil-
ity: 100  µM in DMSO (1%) in embryonic medium; 
Embryotoxicity: 6.25  µM, 12.5  µM, 25  µM, 50  µM, 
100 µM; Cardiotoxicity, hepatotoxicity and neurotox-
icity: 25 µM, 50 µM, 100 µM. Total number of indi-
viduals screened: 550.
3. 2-aminobenzimidalole derived (2amnbzl-d): Molecu-
lar weight: 336.4; Solubility: 50  µM in DMSO (1%) 
in embryonic medium. Embryotoxicity: 6.25  µM, 
12.5  µM, 25  µM, 50  µM, 100  µM, Cardiotoxicity, 
hepatotoxicity, and neurotoxicity: 12.5  µM, 25  µM, 
50 µM. Total number of individuals screened: 550.
Statistical analysis
The comparison between the variables continuous of 
groups with normal distribution and equality of vari-
ances were analyzed using ANOVA statistical test (one 
way) and the Dunnett test for the post-hoc assessment. 
Otherwise, the Kruskal–Wallis and Dunn´s test were 
employed. The difference between survival curves were 
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analyzed by Log-rank (Mantel-Cox) Test with p values 
corrected by Bonferroni´s methodology. The software 
used was the GraphPad Prism 5 (GraphPad Software, 
San Diego, CA, USA). The comparison between the 
categorical variables of two groups were carried out 
using the Z score (https:// www. socsc istat istics. com) 
with p corrected using the Bonferroni´s methodology. 
The dose–response curves were plotted and analyzed 
by Probit Regression using the MedCal 19.8 software 
(MedCalc Software Ltd, Ostend, Belgium). The p val-
ues < 0.05 was considered significant.
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